Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
60 participants
INTERVENTIONAL
2002-12-31
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
VEGF
VEGF
3 sets of injections, at 2 week intervals
2
Placebo
VEGF
3 sets of injections, at 2 week intervals
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VEGF
3 sets of injections, at 2 week intervals
VEGF
3 sets of injections, at 2 week intervals
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be at least 21 years old.
* Have type I or type II diabetes mellitus and require oral anti-hyperglycemic agents or insulin.
* Have peripheral neuropathy related to diabetes.
Exclusion Criteria
* Have a history of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last five years.
* Be unable to meet study requirements, including approximately 7-9 out-patient visits over a 12 month period.
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Losordo, Douglas, M.D.
INDIV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Northwestern University, Northwestern Memorial Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Allan H Ropper, M.D.
Role: PRINCIPAL_INVESTIGATOR
Steward St. Elizabeth's Medical Center of Boston, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Caritas St. Elizabeth's Medical Center Cardiovascular Research/DVM-4-SMC
Boston, Massachusetts, United States
Columbia University Neuropathy Research Center, Neurological Institute
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Caritas St. Elizabeth's Medical Center of Boston
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIH #0104-467
Identifier Type: -
Identifier Source: secondary_id
BB-IND 11572
Identifier Type: -
Identifier Source: org_study_id